Trial Profile
A 12 month, placebo-controlled, multi-center Phase 3 in patients in with oculopharyngeal muscular dystrophy
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 15 Sep 2020
Price :
$35
*
At a glance
- Drugs Trehalose (Primary)
- Indications Oculopharyngeal muscular dystrophy
- Focus Registrational; Therapeutic Use
- 17 Jun 2015 New trial record